The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Betulinic acid and its derivatives: a patent review (2008 – 2013)
Abstract
INTRODUCTION: Betulinic acid (BA) is a triterpenoid that can be obtained from renewable resources. BA is cytotoxic to many human tumor cell lines mainly by apoptosis but cell death might also be triggered by nonapoptotic pathways. Many derivatives have been synthesized to improve the very weak solubility of parent BA and to increase its cytotoxicity as well as its selectivity toward tumor cells. AREAS COVERED: A brief introduction into cancer is given reflecting the different pathways this disease might be treated using chemotherapy using natural product analogs especially triterpenes. The different ways of action of BA in cancer cells are discussed. Finally, this review describes the main synthetic modifications that have been performed and discusses, in short, the structure-activity relationships of these analogs, investigated between 2008 and 2013 including some important publications from early 2014. EXPERT OPINION: A number of patents on BA analogs for the chemotherapy of cancer have been reported between 2008 and 2013. Most of these patents deal with modifications at positions C-3, C-20 and C-28. There are only a few compounds meeting the needs of a sufficient hydrosolubility, while retaining high cytotoxicity and selectivity toward tumor cells. Thus, one might expect that there will be some efforts in developing molecules of improved solubility and to find new and more efficient forms of administration (liposomes, transdermal application and nanoemulsions). An important sideline might be the treatment of the age-dependent degeneration of the macula, a possible caveat of which might be a certain degree of CNS toxicity associated with several derivatives of BA.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Natural products as sources of new drugs over the period 1981–2002
Newman, D. J., Cragg, G. M., & Snader, K. M. (2003) · Journal of Natural Products · doi:10.1021/np030096l · Cited by 3,082
Targeting inflammatory pathways by triterpenoids for prevention and treatment of cancer.
Yadav, V. R., Prasad, S., Sung, B., Kannappan, R., & Aggarwal, B. B. (2010) · Toxins · doi:10.3390/toxins2102428 · Cited by 320
Cited by
Betulin and betulinic acid: triterpenoids derivatives with a powerful biological potential
Hordyjewska, A., Ostapiuk, A., Horecka, A., & Kurzepa, J. (2019) · Phytochemistry Reviews · doi:10.1007/s11101-019-09623-1 · Cited by 298
Cell death mechanisms of plant-derived anticancer drugs: beyond apoptosis
Gali-Muhtasib, H., Hmadi, R., Kareh, M., Tohme, R., & Darwiche, N. (2015) · Apoptosis · doi:10.1007/s10495-015-1169-2 · Cited by 293
Betulin and its derivatives as novel compounds with different pharmacological effects
Amiri, S., Dastghaib, S., Ahmadi, M., Mehrbod, P., Khadem, F., Behrouj, H., Aghanoori, M.-R., Machaj, F., Ghamsari, M., Rosik, J., et al. (2020) · Biotechnology Advances · doi:10.1016/j.biotechadv.2019.06.008 · Cited by 272
Ludwiczuk, A., Skalicka-Woźniak, K., & Georgiev, M. I. (2017) · Pharmacognosy · doi:10.1016/b978-0-12-802104-0.00011-1 · Cited by 258
Martins, W. K., Costa, É. T., Cruz, M. C., Stolf, B. S., Miotto, R., Cordeiro, R. M., & Baptista, M. S. (2015) · Scientific Reports · doi:10.1038/srep12425 · Cited by 32
Metadata
- Authors
- Csuk, R.
- Venue
- Expert Opinion on Therapeutic Patents
- Publisher
- Informa UK Limited
- Published
- 2014-06-07
- Volume
- 24
- Issue
- 8
- Pages
- 913-923
- ISSN
- 1354-3776 (ISSN-L)
- 1744-7674
- OpenAlex
- W2024758998
- Cited by
- 159
- References
- 2
- FWCI
- 5.35
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.